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Supporting Information 
1.  Materials 
Sulfathiazole 2 was purchased from TCI America.  Carbamazepine 3 was purchased from 
VWR International (Pittsburgh, PA).  Compounds 5-methyl-2-[(2-nitrophenyl)amino]-3-
thiophenecarbonitrile (ROY) 1, trans-cinnamic acid 4, and ibuprofen (S- and R,S- forms) 5 were 
purchased from Sigma Aldrich Company (St. Louis, MO).  All compounds were used as 
received.  All solvents used in this study were purchased from Sigma Aldrich Company (St. 
Louis, MO) and used as received.   
The NdFeB magnets (5 cm  5 cm  2.5 cm) were purchased from K&J Magnetics 
(www.kjmagnetics.com) and aligned on top of one another 4.5 cm apart within aluminum 
blocks.  Calibrated density standards (±0.0002 g cm
-3
 at 23°C) were purchased from American 
Density Materials (Stauton, VA; www.densitymaterials.com). Spherical polymer samples were 
purchased from McMaster-Carr (www.mcmaster.com). Polystyrene microspheres with precisely 
defined radii were supplied by Duke Scientific Corporation (www.dukescientific.com), 
Polysciences, Inc. (www.polysciences.com), and Spherotech (www.spherotech.com). All other 
samples and reagents were purchased from Sigma Aldrich (Atlanta, GA) and used without 
further purification.   S-2 
 
Crystals of diffraction quality were characterized using single crystal X-ray diffraction, 
while crystals of poor diffraction quality, or a size too small for single crystal X-ray were 
characterized using Raman spectroscopy or powder X-ray diffraction (PXRD).  Crystal data 
were collected on an APEX II DUO CCD diffractometer and an APEX II CCD diffractometer 
using MoKα radiation ( = 0.7107 Å) at 100K.  Raman spectra were obtained using a Raman 
Microprobe (Kaiser Optical Systems), equipped with a diode laser as the excitation source at 785 
nm, an optical light microscope (Leica), and a CCD camera.  Images of crystals were taken using 
a Zeiss SteREO Discovery V8 microscope. 
 
2.  Polymorphism 
Polymorphs can have differences in the following properties:  density, ρ;
[1] morphology; 
melting  point;
[2]  stability;
[3]  solubility;
[4]  color;
[5]  sensitivity  to  detonation;
[6]  solid-state 
reactivity;
[7]  absorptivity;
[8]  electrical  conductivity;
[9]  magnetic  susceptibility;
[10]  tendency  to 
charge triboelectrically;
[11] flowability;
[12] agglomeration;
[13] tableting,
[14] hygroscopicity,
[15] and 
index of refraction.
[9a,16]   
Polymorphism is of particular interest in the pharmaceutical industry. Drugs made from 
different polymorphic forms of the same active ingredient can vary in stability, solubility and 
dissolution  rate  and  thus  bioavailability.    A  well-known  example  of  a  drug  that  exhibits 
polymorphism  is  Ritonavir,  a  protease  inhibitor.  The  appearance  of  a  second,  less  soluble 
polymorph  of  Ritonavir  resulted  in  the  need  to  reformulate  the  drug  two  years  after  it  was 
launched.
[17] 
 
3.  Methods S-3 
 
3.1. Preparation of crystal polymorphs 
Y and YN polymorphs of ROY.  ROY (0.040 g) was dissolved in 1 mL of isopropanol and 
allowed to crystallize at room temperature.  Yellow needles and prisms formed rapidly over a 
period of three to five minutes.  For seeding experiments, single crystals of form Y isolated from 
MagLev, were placed in a solution containing 20 mg of ROY dissolved in 3 mL of ethanol (200 
proof) after hot filtration.   Product crystals were left to crystallize upon cooling to room 
temperature for a period of 24 hours. 
Polymorphs II and IV of sulfathiazole.  Sulfathiazole, (0.020 g) was dissolved in 2.5 mL of 
ethanol and left to crystallize upon cooling of solvent at room temperature.  Crystals formed over 
a period of twenty-four hours.  For seeding experiments, single crystals of form II isolated from 
MagLev, were placed in a solution containing 20 mg of sulfathiazole dissolved in 2 mL of 
nitromethane after hot filtration.   Product crystals were left to crystallize upon cooling to room 
temperature for a period of one hour.            
α- and β- forms of trans-cinnamic acid.  trans-Cinnamic acid (0.250 g) was dissolved in 1 mL of 
ethanol (200 proof), and left to crystallize at room temperature.  Curved needles and blocks 
formed over a period of five minutes. 
Polymorphs II and III of carbamazepine.  Carbamazepine (0.020 g) was dissolved in 3 mL of 
toluene, and left to crystallize at room temperature.  Long needles and prisms formed over a 
period of twenty-four hours. 
R,S-Ibuprofen.  Single crystals of RS-Ibuprofen were prepared by dissolving 40 mg of solid in 2 
mL of ethanol. The solution was allowed to evaporate at room temperature to afford single 
crystals of the racemate. S-4 
 
S-Ibuprofen. Single crystals of S-Ibuprofen were prepared by gently heating 1 g of solid in 0.5 
mL of diethyl ether in a closed 1.8 mL vial on a hot plate. The solution was then left on the hot 
plate, and crystallization occurred as the plate cooled to room temperature. 
 
 
 
Figure S1.  a) Molecular structure of ibuprofen. b) Photographs of single crystals of R,S-
Ibuprofen and S-Ibuprofen levitating in an aqueous 0.55 M MnCl2 solution containing 0.25 M 
sucrose and 1.0% Tween 20.   
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3.2. MagLev Apparatus  
Figure S2.  Photographs of components for isolating crystal polymorphs.  a)  A plastic cuvette 
composed of polymethyl methacrylate (PMMA).  Holes of either 3/16” or 5/8” diameter were 
drilled approximately 2 mm from the bottom of the cuvette.  Silicone rubber tubing is cut in 3 
inch pieces and placed inside the holes of the cuvette.  Five-minute epoxy is used to seal the 
tubing and cuvette.  Luer locks are placed at the end of the tubes.  Plastic syringes are connected 
to the Luer locks for extraction of the fluid.  b) A cuvette holder made of transparent acrylic 
polymer.  The acrylic block has a slit for the cuvette to slide into the center and a nylon screw to 
further secure the cuvette from moving.  c)  Complete assembly that includes syringes mounted 
on a microscopy stage.   
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Figure S3.  Isolating crystal polymorphs. (i) A syringe is used to withdraw the paramagnetic 
medium and the more dense population of crystals suspended within.  (ii) As the first population 
of crystals from the paramagnetic medium is being removed, the less dense moves with the 
meniscus toward the bottom of the cuvette.  The syringes were disconnected from the tubes and 
the contents were ejected into an empty container. 
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Figure S4.  Photographs of seed crystals isolated from MagLev and products of seeded 
crystallizations of form Y of ROY 1, and form II of sulfathiazole, 2.  The product of form Y of 
ROY increases in size (~2x).  The product crystals of sulfathiazole (form II), show nucleation on 
the surface of the seed crystals.  
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4.   X-ray Crystallographic Information 
Single crystals were taken from each experiment before and after levitation.  The unit cell 
dimensions of each crystal were collected and used to confirm the polymorphic form.  Equation 
2 is used to determine if the unit cell parameters are significantly different before and after 
MagLev, where ∆ is the difference between the two parameters and σ1 is the standard uncertainty 
of the unit cell parameter of a crystal before levitation and σ2 is the standard uncertainty of the  
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unit cell parameter of a crystal after levitation.
[18]  If the difference (∆) between the unit cell 
parameters from Eq.(2), is more than three times the standard uncertainty of the difference, than 
the two unit cells are significantly different.  In contrast, if the difference (∆) between the unit 
cell parameters is less than three times the standard uncertainty of the difference, than the two 
unit cells are not significantly different.  The density of the solids were calculated by 
incorporating the values obtained from the unit cell data into equation 3 as shown below, where ρ 
is the density (g cm
-3), M is the mass of a mole of molecules (kg), NA is Avogadro’s number, V is  
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Z V
MNA
3       (3) 
 
the volume of the unit cell (cm
3), and Z is the number of molecules per unit cell.
[18] 
 
 
4.1. X-ray Crystallographic Tables  
Table S1. Unit cell values obtained from literature and average unit cell values from single 
crystal x-ray crystallography of seven crystals before levitation and after levitation in the 
paramagnetic medium.  Quantitative differences between the average unit cell parameters before 
and after levitation are calculated by using the 3σ rule as calculated from equation 2.  No value is 
significantly different owing to the fact that no value for each parameter is greater than three. 
Compound  Form 
Unit Cell 
Experiment  a  b  c  α  β  γ  V (Å
3) 
1  Y 
Literature   8.5001(8)  16.413(2)  8.5371(5)  90  91.767(7)  90  1190.5(4) 
Before MagLev  8.494(7)  16.08(1)  8.501(6)  90  91.36(3)  90  1161(2) 
After MagLev  8.477(6)  16.036(7)  8.486(4)  90  91.28(3)  90  1153(1) 
3σ test value  2.064  2.699  1.82  N/A  1.835  N/A  2.36 
2 
II 
Literature  8.235(4)  8.550(4)  15.558(8)  90  93.67(1)  90  1093.181 
Before MagLev  8.195(4)  8.48(5)  15.45(1)  90  94.17(4)  90  1078(1) 
After MagLev  8.20(2)  8.56(1)  15.56(8)  90  94.3(2)  90  1090(8) 
3σ test value  0.5008  1.391  1.354  N/A  0.5942  N/A  1.409 
IV 
Literature  10.774(1)  8.467(1)  11.367(1)  90  91.65(1)  90  1036.507 
Before MagLev  10.78(1)  8.480(2)  11.395(4)  90  91.62(2)  90  1041(1) 
After MagLev  10.81(1)  8.498(9)  11.41(1)  90  91.75(5)  90  1048(3) 
3σ test value  1.469  1.797  1.342  N/A  2.278  N/A  1.639 
3 
II 
Literature  35.454(3)  35.454(3)  5.253(1)  90  90  120  5718.321 
Before MagLev  35.20(4)  35.20(4)  5.176(5)  90  90  120  5555(18) 
After MagLev  35.27(7)  35.27(7)  5.17(1)  90  90  120  5579(34) 
3σ test value   0.8747  0.8747  0.02111  N/A  N/A  N/A  0.03969 
III 
Literature  7.534(1)  11.150(2)  13.917(3)  90  92.94(4)  N/A  1167.546 
Before MagLev  7.505(4)  11.06(5)  13.79(1)  90  92.96(4)  90  1143(1) 
After MagLev  7.53(2)  11.091(1)  13.82(8)  90  92.9(2)  90  1153(8) S-11 
 
3σ test value  0.5008  1.391  0.9902  N/A  0.5942  N/A  1.409 
4  α 
Literature  5.582(2)  17.671(4)  7.735(2)  90  96.49(2)  90  758.087 
Before MagLev  5.547(9)  17.51(3)  7.70(1)  90  96.24(1)  90  743(4) 
After MagLev  5.557(8)  17.55(1)  7.73(1)  90  96.29(8)  90  749(3) 
3σ test value  0.7457  1.038  1.036  N/A  0.5726  N/A  0.9869 
 
 
 
4.2. Raman Spectra 
Figure S5. Raman spectra before and after MagLev showing the characteristic stretches of a) 
form YN of ROY, b) β-trans-cinnamic acid, and (c) S- and RS-Ibuprofen.  The characteristic 
Raman shifts are similar before and after levitation showing that the polymorphs have the same 
form before and after MagLev.            
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4.3. Powder X-ray diffraction  
Figure S6. Powder X-ray diffraction patterns of trans-cinnamic acid (signature peaks are 
highlighted with an asterisk, *).  a) The experimental PXRD of the β-polymorph (needle-like 
plates) of trans-cinnamic acid.  b) The simulated PXRD pattern of β-polymorph of trans-
cinnamic acid.  The β-polymorph is confirmed as evidenced by the simulated pattern that 
matches with the experimental.   S-13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4. Densities calculated from X-ray and MagLev  
Table S2. Average values (calculated from seven independent measurements) and the 
uncertainty in measurement of density of all solids.  We calculated the densities of the crystals 
using calibration curves determined from levitation heights using density standards (i.e. glass, 
polymer beads) as previously reported.
[19]     
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Compound  Form  ρ (g/cm
3) X-ray  ρ (g/cm
3) MagLev 
ROY 
YN  1.428
[20]  1.372±0.020 
Y  1.447
[20]  1.450±0.006 
sulfathiazole 
II  1.546
[21]  1.541±0.004 
IV  1.600
[21]  1.580±0.004 
trans-cinnamic acid 
α  1.265
[22]  1.251±0.006 
β  1.286
[23]  1.268±0.006 
carbamazepine 
II  1.235
[24]  1.271±0.004 
III  1.343
[25]  1.320±0.004 
ibuprofen 
S  1.099
[26]  1.091±0.001 
R,S  1.119
[27]  1.108±0.001 
 
 
References 
[1]  A. Gavezzotti, G. Filippini, J. Am. Chem. Soc. 1995, 117, 12299-12305. 
[2]  D. Giron, Thermochim. Acta 1995, 248, 1-59. 
[3]  L. Yu, J. Pharm. Sci. 1995, 84, 966-974. 
[4]  a) J. Bauer, S. Spanton, R. Henry, J. Quick, W. Dziki, W. Porter, J. Morris, Pharm. Res. 
2001, 18, 859-866; b) L.-F. Huang, W.-Q. Tong, Adv. Drug Delivery Rev. 2004, 56, 321-
334. 
[5]  a) L. Yu, J. Phys. Chem. A 2001, 106, 544-550; b) L. Yu, Acc. Chem. Res. 2010, 43, 
1257-1266. 
[6]  R. M. Vrcelj, H. G. Gallagher, J. N. Sherwood, J. Am. Chem. Soc. 2001, 123, 2291-2295. 
[7]  a) M. D. Cohen, G. M. J. Schmidt, F. I. Sonntag, J. Chem. Soc. 1964, 2000-2013; b) T. 
Friščić, L. R. MacGillivray, Chem. Commun. 2009, 773-775. c) M. B. J. Atkinson, A. N. 
Sokolov, D.-K. Bučar, S. V. S. Mariappan, M. T. Mwangi, M. C. Tiedman, L. R. 
MacGillivray, Photochem. Photobiol. Sci. 2011, 10, 1384-1386. 
[8]  P. Li, I. W. Chen, J. E. Penner-Hahn, Phys. Rev. B: Condens. Matter 1993, 48, 10063-
10073. 
[9]  a) G. Barbarella, M. Zambianchi, L. Antolini, P. Ostoja, P. Maccagnani, A. Bongini, E. 
A. Marseglia, E. Tedesco, G. Gigli, R. Cingolani, J. Am. Chem. Soc. 1999, 121, 8920-
8926; b) T. Siegrist, C. Kloc, J. H. Schön, B. Batlogg, R. C. Haddon, S. Berg, G. A. 
Thomas, Angew. Chem. Int. Ed. 2001, 40, 1732-1736. 
[10]  R. A. Heintz, H. Zhao, X. Ouyang, G. Grandinetti, J. Cowen, K. R. Dunbar, Inorg. Chem. 
1998, 38, 144-156. 
[11]  S. Airaksinen, M. Karjalainen, E. Räsänen, J. Rantanen, J. Yliruusi, Int. J. Pharm. 2004, 
276, 129-141. 
[12]  A. Nokhodchi, M. Maghsoodi, D. Hassan-Zadeh, M. Barzegar-Jalali, Powder Technol. 
2007, 175, 73-81. 
[13]  a) Y. Kawashima, T. Niwa, H. Takeuchi, T. Hino, Y. Itoh, S. Furuyama, J. Pharm. Sci. 
1991, 80, 472-478; b) A. Angermann, J. Töpfer, J. Mater. Sci. 2008, 43, 5123-5130. 
[14]  C. Sun, D. W. Grant, Pharm. Res. 2001, 18, 274-280. 
[15]  V. Niederwanger, F. Gozzo, U. J. Griesser, J. Pharm. Sci. 2009, 98, 1064-1074. S-15 
 
[16]  a) Y.-n. Xu, W. Y. Ching, Phys. Rev. B: Condens. Matter 1991, 44, 11048-11059; b) H. 
S. Nalwa, T. Saito, A. Kakuta, T. Iwayanagi, J. Phys. Chem. 1993, 97, 10515-10517; c) 
M. Brinkmann, G. Gadret, M. Muccini, C. Taliani, N. Masciocchi, A. Sironi, J. Am. 
Chem. Soc. 2000, 122, 5147-5157. 
[17]  a) S. R. Chemburkar, J. Bauer, K. Deming, H. Spiwek, K. Patel, J. Morris, R. Henry, S. 
Spanton, W. Dziki, W. Porter, J. Quick, P. Bauer, J. Donaubauer, B. A. Narayanan, M. 
Soldani, D. Riley, K. McFarland, Org. Process Res. Dev. 2000, 4, 413-417; b) J. Bauer, 
S. Spanton, R. Henry, J. Quick, W. Dziki, W. Porter, J. Morris, Pharmaceut Res 2001, 
18, 859-866. 
[18]  W. Clegg, A. J. Blake, R. O. Gould, P. Main, Crystal Structure Analysis: Principles and 
Practice, 2002. 
[19]  K. A. Mirica, S. S. Shevkoplyas, S. T. Phillips, M. Gupta, G. M. Whitesides, J. Am. 
Chem. Soc. 2009, 131, 10049-10058. 
[20]  G. A. Stephenson, T. B. Borchardt, S. R. Byrn, J. Bowyer, C. A. Bunnell, S. V. Snorek, 
L. Yu, J. Pharm. Sci. 1995, 84, 1385-1386. 
[21]  P. McArdle, Y. Hu, A. Lyons, R. Dark, CrystEngComm 2010, 12, 3119-3125. 
[22]  T.-J. Hsieh, C.-C. Su, C.-Y. Chen, C.-H. Liou, L.-H. Lu, J. Mol. Struct. 2005, 741, 193-
199. 
[23]  G. M. J. Schmidt, J. Chem. Soc. 1964, 2014-2021. 
[24]  M. M. J. Lowes, M. R. Caira, A. P. Lotter, J. G. D. Van Watt, J. Pharm. Sci. 1987, 76, 
744-752. 
[25]  a) J. N. Lisgarten, R. A. Palmer, J. W. Saldanha, J. Chem. Crystallogr. 1989, 19, 641-
649; b) V. L. Himes, A. D. Mighell, W. H. De Camp, Acta Crystallogr., Sect. B: Struct. 
Sci 1981, 37, 2242-2245. 
[26]  A. A. Freer, J. M. Bunyan, N. Shankland, D. B. Sheen, Acta Crystallogr., Sect. C: Cryst. 
Struct. Commun. 1993, 49, 1378-1380. 
[27]  J. F. Cryst. Struct. Commun.McConnell, Cryst. Struct. Commun. 1974, 3, 73-75. 
 
 